<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00778583</url>
  </required_header>
  <id_info>
    <org_study_id>024/NITRO-100/03</org_study_id>
    <nct_id>NCT00778583</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Nitrofurantoin 100 mg Capsules Under Fed Conditions</brief_title>
  <official_title>An Open Label, Randomised, Two-Treatment, Four-Period, Two-Sequence, Single-Dose, Crossover, Fully Replicated Bioavailability Study on Nitrofurantoin Formulations Comparing Nitrofurantoin 100 mg Capsules of Ranbaxy Laboratories With Macrobid 100 mg Capsules in Healthy, Adult, Human Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ranbaxy Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ranbaxy Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, randomised, two-treatment, four-period, two-sequence, single-dose, crossover,&#xD;
      fully replicated bioavailability study on Nitrofurantoin formulations comparing&#xD;
      Nitrofurantoin 100 mg capsules of Ranbaxy Laboratories with Macrobid 100 mg capsules in&#xD;
      healthy, adult, human subjects under fed conditions&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was an open-label, randomized, single-dose, four period fully replicate crossover,&#xD;
      relative bioavailability study performed on 40 healthy adult male and. A total of 35&#xD;
      completed the clinical phase of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date type="Actual">December 2003</completion_date>
  <primary_completion_date type="Actual">October 2003</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nitrofurantoin 100 mg capsules of Ranbaxy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Macrobid 100 mg capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrofurantoin 100 mg capsules</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be in the age range of 18-45 years.&#xD;
&#xD;
          -  Be neither overweight nor underweight for his/her height as per the Life insurance&#xD;
             Corporation of India height/weight chart for non-medical cases.&#xD;
&#xD;
          -  Have voluntarily given written informed consent to participate in this study.&#xD;
&#xD;
          -  Be of normal health as determined by medical history and physical examination of the&#xD;
             subjects performed within 14 days prior to the commencement of the study.&#xD;
&#xD;
          -  If female and:&#xD;
&#xD;
          -  Of childbearing potential, is practicing an acceptable method of birth control for the&#xD;
             duration of the study as judged by the investigator(s), such as condoms, foams,&#xD;
             jellies, diaphragm, intrauterine device (IUD), or abstinence; or&#xD;
&#xD;
          -  Is postmenopausal for at least I year; or&#xD;
&#xD;
          -  Is surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or&#xD;
             hysterectomy).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of allergy to nitrofurantoin and/or other related drugs.&#xD;
&#xD;
          -  Any evidence of organ dysfunction or any clinically significant deviation from the&#xD;
             normal, in physical or clinical determinations.&#xD;
&#xD;
          -  Evidence of haemolysis (for glucose-6-phosphotase) deficiency.&#xD;
&#xD;
          -  Presence of disease markers of HIV 1 and 2, Hepatitis B and C viruses or syphilis&#xD;
             infection.&#xD;
&#xD;
          -  Female volunteers demonstrating a positive pregnancy test.&#xD;
&#xD;
          -  Female volunteers who are currently breastfeeding.&#xD;
&#xD;
          -  Presence of values which are significantly different from normal reference ranges (as&#xD;
             defined in Appendix 5) and/or judged clinically significant for haemoglobin, total&#xD;
             white blood cells count, differential WBC count or platelet count.&#xD;
&#xD;
          -  Positive for urinary screen testing of drugs of abuse (opiates and cannabinoids)&#xD;
&#xD;
          -  Presence of values which are significantly different from normal reference ranges (as&#xD;
             defined in Appendix 5) and/or judged clinically significant for serum creatinine,&#xD;
             blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine&#xD;
             aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or&#xD;
             serum cholesterol.&#xD;
&#xD;
          -  Clinically abnormal chemical and microscopic examination of udne defined as presence&#xD;
             of RI3C, WBC (&gt;4/HPF), epithelial cells (&gt;4/HPF), glucose (positive) or protein&#xD;
             (positive).&#xD;
&#xD;
          -  Clinically abnormal ECG or Chest X-ray. History of serious gastrointestinal, hepatic,&#xD;
             renal, cardiovascular, pulmonary, neurological or haematological disease, diabetes,&#xD;
             glaucoma or gout.&#xD;
&#xD;
          -  History of any psychiatric illness which may impair the ability to provide written&#xD;
             informed consent.&#xD;
&#xD;
          -  Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining&#xD;
             from smoking for the duration of each study period.&#xD;
&#xD;
          -  History of drug dependence or excessive alcohol intake on a habitual basis of more&#xD;
             than 2 units of alcoholic beverages per day (1 unify.equivalent to half pint of beer&#xD;
             or ! glass of wine or 1 measure of spirit)or have difficulty in abstaining for the&#xD;
             duration of each study period.&#xD;
&#xD;
          -  Use of any enzyme modi~ing drugs within 30 days prior to Day 1 of this study.&#xD;
&#xD;
          -  Participation in any clinical trial within 12 weeks preceding Day ! of this study.&#xD;
&#xD;
          -  A haemoglobin concentration of less than 7 % of lower limit of reference range e.g. 13&#xD;
             gm % for reference range of 14-18 gm at screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ranbaxy Research Laboratories</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.ranbaxy.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2008</verification_date>
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2008</study_first_posted>
  <last_update_submitted>October 22, 2008</last_update_submitted>
  <last_update_submitted_qc>October 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tausif Monif</name_title>
    <organization>Ranbaxy Research Laboratories</organization>
  </responsible_party>
  <keyword>Bioequivalence Nitrofurantoin capsules</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitrofurantoin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

